Cargando…

Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands

AIM: This study explores clinical outcome in cytochrome P450 2C19 (CYP2C19)-related poor metaboliser patients treated with either clopidogrel or prasugrel after percutaneous coronary intervention (PCI) and investigates whether this could be cost-effective. METHODS AND RESULTS: This single-centre, ob...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deiman, B. A. L. M., Tonino, P. A. L., Kouhestani, K., Schrover, C. E. M., Scharnhorst, V., Dekker, L. R. C., Pijls, N. H. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bohn Stafleu van Loghum 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039130/ https://www.ncbi.nlm.nih.gov/pubmed/27573042 http://dx.doi.org/10.1007/s12471-016-0873-z

Ejemplares similares

Development of a real-time NASBA for respiratory syncytial virus
por: van Aarle, P., et al.
Publicado: (2006)

Sensitive detection and quantification of SARS-CoV-2 by multiplex droplet digital RT-PCR
por: de Kock, Remco, et al.
Publicado: (2020)

Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions
por: Summaria, Francesco, et al.
Publicado: (2015)

Antiplatelet therapy with CABG: chaos in the Netherlands
por: Verheugt, F. W. A.
Publicado: (2017)

Cost-effectiveness of antiplatelet drugs after percutaneous coronary intervention
por: Wisløff, Torbjørn, et al.
Publicado: (2016)

Incidence of major adverse cardiovascular events with genotype test guided antiplatelet treatment strategy after percutaneous coronary intervention
por: Ramesh, S., et al.
Publicado: (2020)

Erratum to: Antiplatelet therapy with CABG: chaos in the Netherlands
por: Verheugt, F. W. A.
Publicado: (2017)

Oral antiplatelet therapy in the elderly undergoing percutaneous coronary intervention: an umbrella review
por: Biondi-Zoccai, Giuseppe, et al.
Publicado: (2020)

Daylight saving time does not seem to be associated with number of percutaneous coronary interventions for acute myocardial infarction in the Netherlands
por: Derks, L., et al.
Publicado: (2021)

Individualized intensified antiplatelet therapy based on platelet reactivity testing reduces the incidence of cardiovascular events in patients undergoing percutaneous coronary intervention
por: Spartalis, Michael, et al.
Publicado: (2017)

The Effect of Genotyping on the Number of Pharmacotherapeutic Gene–Drug Interventions in Chronic Kidney Disease Patients
por: Kerskes, Catharina H. M., et al.
Publicado: (2023)

Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention
por: Patel, Vardhaman, et al.
Publicado: (2014)

CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
por: Beitelshees, Amber L., et al.
Publicado: (2022)

Antiplatelet Therapy and Percutaneous Coronary Interventions
por: Davanzo, Rene Hameau, et al.
Publicado: (2021)

Shortening Dual Antiplatelet Therapy Duration in High-Risk Patients Undergoing Percutaneous Coronary Intervention
por: Greco, Antonio, et al.
Publicado: (2023)

Intensity of antiplatelet therapy and percutaneous coronary intervention
por: Aronow, Wilbert S
Publicado: (2009)

Impact of Anemia and Dual Antiplatelet Therapy on Mortality in Patients Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents
por: Wang, Huili, et al.
Publicado: (2015)

A novel de-escalation antiplatelet therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Li, Yachao, et al.
Publicado: (2023)

Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how
por: Muthspiel, Marie, et al.
Publicado: (2022)

Report on outcomes of valve-in-valve transcatheter aortic valve implantation and redo surgical aortic valve replacement in the Netherlands
por: van Steenbergen, G. J., et al.
Publicado: (2021)

Percutaneous Nephrolithotomy in Patients on Chronic Anticoagulant/Antiplatelet Therapy
por: Nerli, R B, et al.
Publicado: (2012)

Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
por: ten Berg, Jurriën M, et al.
Publicado: (2001)

Income and antiplatelet adherence following percutaneous coronary intervention
por: LaRosa, Anna R., et al.
Publicado: (2022)

Antiplatelet combinations for prevention of atherothrombotic events
por: Bollati, Mario, et al.
Publicado: (2011)

Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention
por: Cavallari, Larisa H., et al.
Publicado: (2018)

Association of Frailty With Antiplatelet Response Among Elderly Chinese Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
por: Liu, Yang, et al.
Publicado: (2020)

Meta-analysis of Unguided Deescalation of Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Mohamed, Mohamed M. G., et al.
Publicado: (2022)

CYP2C19 genotype-directed P(2)Y(12) inhibitor antiplatelet therapy normalizes risk for major adverse cardiovascular events after percutaneous coronary intervention
por: Stys, Tomasz P., et al.
Publicado: (2021)

Safety and Feasibility of Percutaneous Gastrostomy Placement in Patients on Antiplatelet Therapy
por: Tramel, Richard, et al.
Publicado: (2021)

Development of a Multiplex and Cost-Effective Genotype Test toward More Personalized Medicine for the Antiplatelet Drug Clopidogrel
por: Jeong, Hye-Eun, et al.
Publicado: (2014)

Triple versus dual antiplatelet therapy for coronary heart disease patients undergoing percutaneous coronary intervention: A meta-analysis
por: ZHOU, HONG, et al.
Publicado: (2013)

Resolution of left ventricular postinfarction thrombi in patients undergoing percutaneous coronary intervention using rivaroxaban in addition to dual antiplatelet therapy
por: Makrides, Constantinos Andreas
Publicado: (2016)

A cost of illness study of hypoglycaemic events in insulin-treated diabetes in the Netherlands
por: de Groot, Saskia, et al.
Publicado: (2018)

Assessment of exercise-induced changes in von Willebrand factor as a marker of severity of aortic stenosis
por: Zelis, Jo M, et al.
Publicado: (2020)

Genotype- and Phenotype-Directed Personalization of Antiplatelet Treatment in Patients with Non-ST Elevation Acute Coronary Syndromes Undergoing Coronary Stenting
por: Ahn, Sung Gyun, et al.
Publicado: (2013)

Effectiveness of dual antiplatelet de-escalation therapy on the prognosis of patients with ST segment elevation myocardial infarction undergoing percutaneous coronary intervention
por: Zhao, Zhigang, et al.
Publicado: (2023)

Efficacy and safety of different dual antiplatelet strategies in patients undergoing percutaneous coronary intervention: A systematic review and network meta‐analysis
por: Wongsalap, Yuttana, et al.
Publicado: (2023)

The cost associated with administering risperidone long-acting injections in the Australian community
por: Dalton, Andrew, et al.
Publicado: (2011)

Safety of Percutaneous Dilatational Tracheotomy in Patients on Dual Antiplatelet Therapy and Anticoagulation
por: Lüsebrink, Enzo, et al.
Publicado: (2019)

Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era
por: Han, Jennie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0bvd3c8s2ctnt43jefefhikh85